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Abstract

Downloaded from http://ahajournals.org by on June 11, 2021

Background: Transcatheter aortic valve replacement (TAVR) is a transformative therapy for
aortic stenosis. Despite rapid improvements in technology and techniques, serious complications
remain relatively common and are not well described by single outcome measures. The purpose
of this study was to determine if there is site-level variation in TAVR outcomes in the United
States using a novel 30-day composite measure.
Methods: We performed a retrospective cohort study using data from the STS/ACC TVT
Registry to develop a novel ranked composite performance measure that incorporates mortality
and serious complications. The selection and rank order of the complications for the composite
was determined by their adjusted association with 1-year outcomes. Sites whose risk-adjusted
outcomes were significantly more or less frequent than the national average based on a 95%
probability interval were classified as performing worse or better than expected.
Results: The development cohort consisted of 52,561 patients who underwent TAVR between
January 1, 2015 and December 31, 2017. Based on the associations with 1-year risk-adjusted
mortality and health status, we identified four periprocedural complications to include in the
composite risk model in addition to mortality. Ranked empirically according to severity, these
included stroke, major, life-threatening or disabling bleeding, stage III acute kidney injury, and
moderate or severe peri-valvular regurgitation. Based on these ranked outcomes, we found that
there was significant site-level variation in quality of care in TAVR in the United States.
Overall, better than expected site performance was observed in 25/301 (8%) of sites;
performance as expected was observed in 242/301 sites (80%); and worse than expected
performance was observed in 34/301 (11%) of sites. Thirty-day mortality, stroke, major, lifethreatening or disabling bleeding, and moderate or severe peri-valvular leak were each
substantially more common in sites with worse than expected performance as compared with
other sites. There was good aggregate reliability of the model.
Conclusions: There are substantial variations in the quality of TAVR care received in the United
States, and 11% of sites were identified as providing care below the average level of
performance. Further study is necessary to determine structural, process-related, and technical
factors associated with high- and low-performing sites.
Key Words: cardiac valve prosthesis; performance measurement; quality outcomes;
transcatheter aortic valve implantation
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Clinical Perspective

What is new?
•

Transcatheter Aortic Valve Replacement(TAVR) is a breakthrough technology that has
revolutionized the care of patients with aortic stenosis.

•

While the use of TAVR has grown rapidly, it is unknown if there are site-level
differences in the quality of care

•

Using data from the Transcatheter Valve Therapy Registry, a national registry of all
commercial TAVRs in the United States, we found significant variation in the quality of
care delivered occurring at the site level.

What are the clinical implications?
•

TAVR programs may use the feedback generated from this analysis to study and improve
processes of care and clinical outcomes.

Downloaded from http://ahajournals.org by on June 11, 2021
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Introduction
Transcatheter aortic valve replacement (TAVR) is a rapidly developing technology for the
treatment of aortic stenosis that was first approved for commercial use in 2011 by the Food and
Drug Administration(FDA) and subsequent coverage by the Centers for Medicare and Medicaid
Services (CMS)in 2012[1-3]. Both mortality and major complications after TAVR have been
declining due to advances in technology, techniques, and expansion of TAVR to healthier
patients.[4] Nonetheless, several publications from the STS/ACC Transcatheter Valve Therapies
(TVT) Registry as well as other international registries have documented hospital-specific
variation in short-term mortality after TAVR, suggesting differential quality of care is being
provided at the hospital level.[5,6]
As part of the initial coverage process, the Centers for Medicare and Medicaid Services
(CMS) mandated that all TAVR procedures in the United States be captured in a prospective
Downloaded from http://ahajournals.org by on June 11, 2021

clinical registry with one year follow-up.[3] In 2019, CMS published an update to their 2012
coverage determination for TAVR recommending continuation of the registry and the
development of evidence linking procedure-related complications with longer term patient health
outcomes. [7] In their National Coverage Determination (NCD), CMS specifically stated that a
periprocedural composite metric incorporating relevant patient health outcomes was a priority
and may eventually replace volume thresholds in their Coverage with Evidence Decision(CED)
regarding TAVR reimbursement.[7]
In an effort to assist patients in their health care choices and to respond to CMS guidance,
we therefore sought to develop and validate a performance measure for TAVR. The broad goals
of this performance measure were to serve as a national benchmark for quality-of-care
monitoring and to support both local quality improvement efforts as well as national efforts to
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use quality rather than volume requirements to maintain TAVR programs. Based, in part, on
CMS recommendations, we modeled a ranked composite endpoint including both fatal and nonfatal complications with rankings chosen based on the association of these complications with
late mortality as well as patient-reported health status.

Methods
The data, analytic methods, and study are available from the data analytic center on reasonable
request via established access pathways to the TVT registry.
STS/ACC TVT Registry
The STS/ACC TVT registry was created in 2011 through partnership between the Society of
Thoracic Surgeons and the American College of Cardiology in collaboration with the FDA and
the Centers for Medicare and Medicaid services.[8]

One of the original mandates of the TVT

Downloaded from http://ahajournals.org by on June 11, 2021

registry was to develop risk models specifically tailored for the TAVR population to allow for
benchmark comparisons of risk-adjusted outcomes among centers. Valve Academic Research
Consortium (VARC) standardized definitions of outcomes variables are captured periprocedurally and at one year.[9] Data elements are completed according to a standardized data
dictionary and validated for completeness and accuracy by the analytic center. A random audit
of 10% of data elements is performed either on-site or remotely. This study was approved by
the Duke University Institutional Review Board (ClinicalTrials.gov Identifier: NCT01737528).
Patient-Reported Health Status
In addition to clinical outcomes, based on the CMS mandate, the TVT registry collects data on
patient-reported health status at baseline, 1 month, and 1-year after TAVR using the short
version of the Kansas City Cardiomyopathy Questionnaire (KCCQ-12). [10] The KCCQ-OS is

5

10.1161/CIRCULATIONAHA.120.051456

an overall summary score derived from the four measured KCCQ-12 domains (physical
limitation, symptom frequency, quality of life, social limitation). It ranges from 0 to 100 with
higher scores indicating less symptom burden and better quality of life. Differences in the
KCCQ-OS of 5, 10, and 20 points correspond to small, moderate or large clinical changes at the
individual patient-level.[11]
Study Cohort
For the purposes of model development, we included all patients undergoing TAVR for
symptomatic aortic stenosis between Jan 1, 2015 and Dec 31, 2017. Based on conventions
established for the TVT 30-day mortality model, data from hospitals with >10% missing data for
the outcome variable and other key study variables were excluded. Baseline patient
characteristics are presented in Table 1. We limited the analysis to a 3-year time period to ensure
the use of recent generation devices and to allow for one-year follow-up in all patients.
Downloaded from http://ahajournals.org by on June 11, 2021

Additionally, with the expansion of TAVR centers over the years since commercial approval in
2011, the longer time interval may potentially mitigate learning curve issues a program may
experience in its early implementation.[12] Only the first TAVR per patient during the study
period was included.
Ranked Composite Outcome Measure
Composite performance measures of procedures in the cardiovascular field are generally
composed of mortality and non-fatal outcomes that cause substantial morbidity, which are
typically selected by expert panels. Although the most common approach to analyzing such
composite endpoints for performance measurement is to combine them into a single binary
outcome, different nonfatal outcomes often have very different effects on the long term health
status of the patient; as such, it may not be appropriate to treat them equally. Subjective
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weighting of non-fatal outcomes by expert panels may introduce bias by failing to account for
patient preferences.[13] Based on the assumption that patients would prefer to be alive and well
after their TAVR, we used a strategy that incorporated one-year survival to empirically guide the
ranking of non-fatal outcomes.
The components of the composite endpoint were determined by establishing which nonfatal periprocedural complications were independently with one-year mortality and the strength
of this association. Details of this analysis, which was similar to previous work by Arnold and
colleagues [14] are described in detail in Section 1 of the Statistical Supplement . The final
hierarchical composite endpoint, as derived from the one year mortality association, consisted of
(1) death; (2) stroke; (3) Stage III acute kidney injury (AKI); (4) major, life-threatening, or
disabling bleeding; (5) moderate or severe peri-valvular regurgitation; and (6) none of the
aforementioned complications. Definitions of the outcomes included in the final global rank
Downloaded from http://ahajournals.org by on June 11, 2021

composite measure are presented in Table 2. Peri-valvular regurgitation was determined at the
latest echocardiogram within the 30-day time frame. If a patient experienced multiple outcomes
captured in the overall rank composite measure, the outcome with the highest rank was assigned.
We also studied the association between these non-fatal complications and one year patient
reported health status by KCCQ-OS and found them to be similar in both direction and
magnitude to the mortality associations.
Statistical Methods
Statistical analyses were performed using SAS software version 9.4 (SAS Institute, Inc., Cary,
North Carolina) and R version 3.4 (R Core Team, 2019). Hospital-specific outcomes were
adjusted for 46 case mix factors chosen to match the most recently published TVT TAVR
mortality model (See Supplemental Table 1) [15]. We used a generalized linear mixed model
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(GLMM) proportional odds model with logit link and multinomial distributional assumption,
incorporating a random effect for site to account for potential clustering and to produce unbiased
standard errors. Parameters were estimated by maximum likelihood using SAS PROC
GLIMMIX software. The statistical framework was a hierarchical proportional odds regression
model with random hospital intercepts [16]. The proportional odds methodology is an extension
of binary logistic regression to accommodate multiple ordered outcome categories. We included
hospital-level random effects in order to estimate hospital-level variation while accounting for
the multi-level data structure and to obtain reliability-adjusted estimates of each individual
hospital's performance.
To facilitate interpretation, performance estimates from the model are expressed in terms
of a "site difference" metric that resembles the "win ratio" and "net benefit" approaches
developed for assessing ranked outcomes in clinical trials based on the numbers of winners and
Downloaded from http://ahajournals.org by on June 11, 2021

losers in paired analyses [17, 18]. Conceptually, the site difference involves pairing each patient
treated by the TAVR hospital of interest with a hypothetical patient having identical risk factors
who is treated by an average-performing reference hospital. The site difference is calculated as
the model-predicted proportion of winning pairs minus losing pairs where "winning pair" means
that the hospital of interest's patient had a better outcome compared to the reference hospital and
"losing pair" means that the reference hospital's patient had a worse outcome compared to the
reference hospital. A site difference greater than zero implies that a hospital’s outcomes are
better than expected in light of its case mix, whereas a site difference value less than zero implies
the opposite.
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To account for uncertainty due to chance fluctuations in a hospital's outcomes, we
calculated a 95% empirical Bayes probability interval around each hospital's site difference
estimate. Hospitals were then categorized as performing better than expected, worse than
expected, or as expected based on whether the 95% probability interval fell entirely below zero,
entirely above zero, or was overlapping with zero. There was no attempt to pre-specify the
proportion of hospitals that would be categorized as performing within or outside the expected
range. Full details of the model are presented in the Supplemental Methods Appendix.
Analysis of Individual Endpoints Stratified by Hospital Categories:
To ensure that hospital classifications based on the ordinal composite endpoint were consistent
with clinical expectations, we fit hierarchical binary logistic regression models for each
individual endpoint in the composite and used these models to compare risk-adjusted outcomes
across hospitals stratified by their performance on the composite metric (better than expected, as
Downloaded from http://ahajournals.org by on June 11, 2021

expected, worse than expected). Covariates for this analysis were identical to those for the
composite model. Expected rates of each complication were calculated for each group of
hospitals (better, same, worse than expected) by averaging predicted risk estimates across all
patients within the group. These expected rates were then compared with the observed outcomes
by calculating observed to expected ratios (observed rate/expected rate).
Reliability
Aggregate reliability (i.e., the ability of the performance measure to distinguish between actual
differences in performance and measurement error) was estimated using Monte Carlo simulation
as described in the Supplemental Methods Appendix. Based on previous work, ideal thresholds
for reliability are typically between 0.7 and 1.0 with acceptable thresholds as low as 0.5 [19].
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Missing data
Covariates for case mix adjustment were generally complete with the exception of carotid
stenosis (14.9%), baseline KCCQ-OS (missing in 2.6%) and gait speed (missing in 14.5%). To
reduce bias and maintain consistency with the CMS NCD mandate to include patient health
status, we limited the analysis to sites with ≥90% completeness for baseline KCCQ-OS and gait
speed. Excluded sites were generally very similar to sites included in the analysis. Excluded
sites had a numerically higher mean annualized volume but similar geographic distribution by
region, urban versus rural setting and teaching versus non-teaching. Comparison of the
characteristics of included and excluded sites is presented in Supplemental Table 2. Among
included sites, we imputed missing covariate data to the median of continuous variables and the
most common category of categorical variables. We performed sensitivity analyses regarding the
inclusion of KCCQ-OS and gait speed in the risk model. This included running the model
Downloaded from http://ahajournals.org by on June 11, 2021

without the exclusion for >90% completeness for the KCCQ-OS and gait speed which left a total
of 444 eligible sites and 112 sites remained excluded due to less than 90% completeness for the
primary endpoint. This increased the number of patients from 52,561 to 85,650. We analysed
the classification of sites both in the larger overall cohort of 444 sites as well as specifically
looking at any reclassifications of the original 301 sites based on the model derived from the 444
sites.

Results
Patient Cohort
Between January 1, 2015 and December 31, 2017, a total of 114,121 patients underwent TAVR
and were included in the TVT Registry. After excluding patients with missing data for
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components of the global rank endpoint (n=1656) and patients treated at sites with <90%
complete baseline data for the KCCQ or 5MWT (n=59,904 patients), the analytic cohort
included 52,561 records from 301 hospitals. Baseline characteristics of those patients who were
included in the primary analytic cohort and those who were excluded are summarized in
Supplemental Table 3. Overall the included versus the excluded patients were very similar in
baseline demographic features.
Selection of Composite Measure Endpoints
Non-fatal 30-day complications that were associated with increased risk of one year mortality
included stroke (adjusted HR 2.10; 95% CI 1.65 to 2.87; p<0.001), major or life-threatening
bleeding (adjusted HR 1.92; 95% CI 1.42 to 2.60, p<0.001), modified AKIN Stage III acute
kidney injury (adjusted HR 1.81; 95% CI 1.38 to 2.37, p<0.001), and moderate or severe perivalvular aortic regurgitation (adjusted HR 1.50; 95% CI 1.24 to 1.81; p<0.001). Major vascular
Downloaded from http://ahajournals.org by on June 11, 2021

complications (in the absence of bleeding), mild peri-valvular aortic regurgitation, and new
permanent pacemaker implantation were not associated with one year mortality.
Similarly, non-fatal periprocedural complications were also associated with 1-year patient
reported health status as assessed by the KCCQ-OS score. With only minor exceptions, the
overall directionality of the associations were similar to the association of these complications on
mortality. Any stroke (adjusted impact on 1-year KCCQ-OS -5.8 points; 95% CI -9.2 to -2.4,
p<0.001) and moderate or severe peri-valvular regurgitation (adjusted KCCQ-OS impact -2.0
points; 95% CI-3.8 to -0.30, p=0.021) were independently associated with poorer adjusted
KCCQ-OS at one year. Modified AKIN Stage III acute kidney injury (adjusted KCCQ-OS
impact -3.3 points; 95% CI -6.8 to 0.28, p=0.07) and major or life-threatening bleed (adjusted
KCCQ-OS impact 0.4 points; 95%CI -2.0 to 1.2, p=0.619) were not associated with one year
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KCCQ-OS but were retained in the global rank composite measure, given their strong
associations with 1-year mortality.
Based on these associations, the final global ranking for the ranked composite measure in
order of decreasing severity were death, stroke, major or life-threatening/disabling bleeding,
modified AKIN Stage III acute kidney injury, moderate or severe peri-valvular aortic
regurgitation (Table 3). Overall, at least one of the complications occurred in 14.1% of patients,
whereas 85.9% of patients had none. In the hierarchical analysis, the most common
complication was major bleeding, which occurred in 5.8% of patients; this was followed by
death (3.2%), moderate or severe PVL (2.5%), stroke (2.0%), and stage III AKI (0.6%). The
associations between endpoints is presented in Supplemental Table 4.
Site-Specific Performance Estimates
Site-specific performance estimates according to the global rank composite metric are displayed
Downloaded from http://ahajournals.org by on June 11, 2021

using the site-difference methodology in Figure 1. The estimated site difference compared with
the average site ranged from +6% in the best performing site to -16% in the worst performing
site. Overall, better than expected site performance was observed in 25/301 (8%) of sites, as
expected performance was observed in 241/301 sites (80%), and worse than expected
performance was observed in 34/301 (11%) of sites. The overall risk-adjusted model is provided
in Supplemental Table 5.
Outcomes of individual endpoints within composite performance categories
Adjusted observed to expected (O:E) ratios of the individual endpoint components according to
the 3 levels of site performance are summarized in Table 4. Sites with better than expected
performance on the global rank composite metric showed lower O:E ratios for all components of
the global rank composite measure compared with the sites that performed as expected or worse

12

10.1161/CIRCULATIONAHA.120.051456

than expected. Similarly, sites with worse than expected performance on the global rank
composite demonstrated consistently higher O:E ratios than the other sites. The largest
differences favoring the better than expected sites were observed in the incidence of major, life
threatening or disabling bleeding and moderate or severe peri-valvular leak.
Model Performance in Contemporary Data
The initial model was derived using data from January 1, 2015 to December 31, 2017. In order
to assess outcomes in the most recent available data, we also ran the composite model on
procedures performed between July 1, 2016 and June 30, 2019. We chose a 3-year time period
for this analysis despite the fact that it overlaps partly with the derivation cohort, because the
performance measure is intended to be applied to 3-year rolling data. This updated dataset
included 364 eligible sites and 86,006 patients. The overall rate of mortality or major
complications was 11.9%, similar to that in the development cohort (Supplemental Table 6). In
Downloaded from http://ahajournals.org by on June 11, 2021

the contemporary cohort, 45/365 (12%) of sites performed worse than expected, 279/364 (77%)
performed as expected, and 40/364 (11%) performed better than expected.
Model Reliability
Based on Monte Carlo simulation, reliability for the overall study cohort was 0.64 indicating
moderate reliability. When the analytic cohort was restricted to sites with at least 25 cases over 3
years, reliability increased to 0.65 (Supplemental Table 7), and reliability exceeded 0.7
(indicating high reliability) once site volume exceeded 100 cases over the 3 year period.
Impact of Missing KCCQ-OS and Gait Speed
The model results run without exclusions for data completeness of KCCQ-OS and gait speed
were nearly identical to our main findings with 36/444 (8%) sites performed better than
expected, 353/444 (80%) sites performed as expected, and 55/444 (12%) of sites performed
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worse than expected. When we reexamined the classification of the 301 sites within the original
cohort when using the larger 444 site model, 3 of the 301 sites were reclassified: one site was
reclassified from “Better Than Expected” to “As Expected”, one site was reclassified from “As
Expected” to “Better Than Expected”; and one site was reclassified from “Worse Than
Expected” to “As Expected”.

Discussion
TAVR is a breakthrough technology that has been systematically evaluated in large scale
randomized clinical trials that have established its safety and efficacy compared with both
medical therapy and surgical aortic valve replacement in a variety of patient populations.
Reports from the TVT registry have demonstrated that, on average, real-world outcomes are
similar to those reported in the pivotal trials [20]. As TAVR is disseminated to an increasing
Downloaded from http://ahajournals.org by on June 11, 2021

number of sites and a wide range of aortic stenosis patients, however, concerns remain regarding
variations in the quality of care delivered. Although greater procedural volume has been shown
to correlate with better TAVR outcomes this correlation only accounts for fraction of variability
in site performance [5]. As such, there is interest on the part of multiple stakeholders in
developing more direct approaches to evaluating site-level performance. In the current study, we
have used a novel approach to benchmarking, based on an empirically-derived ranked composite
endpoint that accounts for the association between early morbid outcomes and 1-year survival
and patient health status. Using this approach, we found that in current U.S. practice, there is a
significant variation in performance between hospitals. This was observed in both the derivation
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cohort encompassing calendar years 2015-2017 and in the more recent cohort from July 1, 2016
to June 30, 2019.
In order to understand the quality of care that patients receive, performance measurement
has become a standard in cardiovascular intervention and surgery. Quality initiatives originally
focused on risk-adjusted mortality after coronary artery bypass grafting (CABG) but over the
past 30 years have expanded to include valvular surgery, congenital heart surgery and a wide
range of interventional cardiology and electrophysiology procedures [21-24]. As mortality rates
for most cardiovascular procedures have declined over the past 2-3 decades, there has been
greater emphasis on understanding quality of care among the patients who survive these
interventions [15]. This shifting focus has led to the development of composite measures which
include both morbidity and mortality, which now form the basis of the publicly reported ratings
for major cardiac procedures.[25]
Downloaded from http://ahajournals.org by on June 11, 2021

To our knowledge, our approach to development and reporting of the TVT composite
outcome model for TAVR is unique. Rather than relying on a traditional binary composite
endpoint with endpoint selection based on expert consensus, we used a combination of novel
statistical approaches and empirical data on the association between short-term procedural
complications and mortality and health status outcomes to derive an outcome benchmark that is
rigorous, statistically reliable, and patient-centered. Since TAVR is performed nationally in a
large volumes (currently >70,000 procedures/year), the need to include surrogate structural or
process measures was minimized. Based on the NCD by CMS regarding qualifications for a
TAVR center, TAVR is typically performed in centers with a substantial volume of PCI,
structural heart, and surgical AVR procedures, and performed by experienced multidisciplinary
teams including a surgeon and an interventional cardiologist. Participation in the STS ACC TVT
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registry is mandatory for reimbursement. Hence, traditional structural measures of quality such
as program volume, access to advanced imaging capabilities or procedural suites, use of
multidisciplinary teams and participation in outcomes registries have already been systematically
incorporated into the site selection process for TAVR.
With a focus on outcomes for performance measurement, various strategies to select nonfatal outcomes were considered. These strategies included patient focus groups, expert
consensus or Delphi panels, and data-driven empirical approaches. In contrast to most other
procedural registries that focus exclusively on in-hospital or 30-day outcomes, the STS/ACC
TVT registry, as part of its CMS mandate, captures select 1-year clinical outcomes including
mortality and also patient-reported health status as measured by the KCCQ. Informing hospitallevel performance measures with patient reported outcomes has potentially distinct advantages
over traditional techniques by allowing the quality of an episode of care to be assessed according
Downloaded from http://ahajournals.org by on June 11, 2021

to the impact of the therapy and periprocedural complications on a patient’s health status over
the life of the patient. We selected the endpoints and their rank order using empirical data from
the TVT registry on the association between the complications of interest and both 1-year
mortality and health status. This represents one of the first hospital-level performance models to
incorporate formal assessment of health status—both as a risk-adjustment factor as well as in the
selection and ranking of non-mortality endpoints for the composite measure. Future endeavors
may involve directly using one-year KCCQ as one of the primary endpoints, although one year
health status may be influenced by a large number factors that are either not related to the index
TAVR procedure, or out of the control of the TAVR implanting center.
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The results of our analyses performed as part of model development and validation have
important clinical and policy implications. Importantly, after adjusting for case mix, sites with
worse than expected performance had substantially higher rates of mortality and all categories
major morbidities compared with sites that performed as expected or better than expected. These
findings suggest that there is a meaningful performance gap in TAVR at a modest number of US
centers.
Our approach to measuring and benchmarking quality has a number of important
strengths. In particular, the use of ranked endpoints in this TAVR performance measure
provides a high degree of overall reliability despite the variability in site volumes. An additional
strength of our approach is that the model is highly adaptable to fundamental changes in the
patient population. As TAVR expands into the lower risk cohort of patients, different outcomes
may become more relevant to quality of life and mortality may become less common. The
Downloaded from http://ahajournals.org by on June 11, 2021

technique utilized in this analysis allows for these changes to be incorporated into an updated
ordinal ranking without re-visiting a Delphi-type consensus process for each iteration of the
model. Finally, it is important to note that this measure has undergone a period of public
commentary and sensitivity analyses to ensure internal and external validity and alignment with
other quality efforts. This is in accordance with the 2019 update of the CMS TAVR NCD which
specifically proposed both public reporting and linking early procedural outcomes to later patient
health status as an overall measure of quality [7]. Indeed, in the most recent TAVR NCD, CMS
explicitly stated that such a quality metric may eventually replace TAVR volume as one of the
primary requirements for maintaining a TAVR program.
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Limitations
This study should be considered in light of several limitations. Missing baseline KCCQ-12 and
gait speed data significantly limited the number of sites included in this analysis. Their inclusion
in the final model was based on evidence that these covariates are associated with both early and
late TAVR outcomes [15,26] as well as concern that exclusion of these covariates could
potentially bias the risk model against sites that treat more complex patients. In light of the
challenges posed by incomplete baseline data, significant educational efforts are being made to
improve data completeness, and the inclusion of these variables within the TVT registry and
their collection remain mandated by CMS. Given recent experience with similar data gaps in by
the STS registry (personal communication, David M. Shahian, MD 9/4/2020), we anticipate
improved compliance with these data elements in future iterations of this model. Sensitivity
analyses showed that removal of the 90% completeness exclusion for KCCQ-OS and gait speed,
Downloaded from http://ahajournals.org by on June 11, 2021

thereby allowing for a larger number of sites (444 sites), resulted in nearly identical proportions
of classification into the outcome groups and nearly no re-classification within the original 301
site cohort.
Our use of 30-day (rather than in-hospital) outcomes as the basis for the model is based
on the assumption that 30-day outcomes are largely dependent on the performance of the hospital
and team performing the TAVR. Nonetheless, we recognize that after discharge other providers
and institutions may have impacted the occurrence and management of the outcomes included in
this composite measure. On the other hand, a performance measure based on only events
occurring during the index hospital admission has its own limitations leading to under-reporting
of complications related to the TAVR procedure and the patient selection process. Thus, the 30day time frame was considered as a reasonable compromise.
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Conclusions
Using a novel measure based on ranked 30-day outcomes, we have identified significant
hospital-level variation in mortality and major complications after TAVR procedures in the
United States. This metric is scheduled to be publicly reported beginning in mid-2021 as part of
ongoing STS/ACC TVT Registry quality improvement initiatives. Further study is necessary to
determine the impact of these measures on TAVR outcomes and structural, process-related, and
technical factors associated with high and low-performing sites.
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Table 1. Baseline Patient Characteristics
Characteristic
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Overall Population
(n=52,561)
82 (76, 87)
53.5
38.4
5.8
3.7
63 (48, 78)
58 (50, 60)
23.2
14.3
34.4
23.4
11.9
2.2
14.9
39.3
38.2
18.5
22.0
28.3
11.9
10.2
7.0
4.0
7.6

Missing (%)

Age, yrs
0.0
Male Sex, %
0.0
Diabetes mellitus, %
0.1
Current smoker, %
<0.1
Currently on dialysis, %
0.1
GFR, ml/min/1.73 m2
0.3
LVEF, %
0.6
Prior MI, %
0.2
Prior pacemaker, %
0.1
Prior PCI, %
0.1
Prior CABG, %
0.1
Prior aortic valve procedure, %
0.1
Prior non-aortic valve procedure, %
0.2
NYHA Class IV, %
0.5
Atrial fibrillation/flutter, %
0.1
Conduction defect, %
0.5
Prior stroke or TIA, %
<0.1
Carotid stenosis, %
14.9
Peripheral arterial disease, %
0.1
Severe chronic lung disease, %
0.5
Home oxygen, %
<0.1
Hostile chest, %
<0.1
Porcelain aorta, %
0.1
Non-femoral access, %
0.3
Acuity
0.0
Elective, %
90.8
Urgent, %
6.1
Shock/Inotrope/Support device, %
2.7
Emergency/Salvage/Cardiac arrest, %
0.4
KCCQ-OS
43 (26, 63)
2.6
5MWT, seconds
7 (6, 10)
14.5
Continuous variables are described as medians with 25th and 75th percentiles
GFR = glomerular filtration rate; LVEF = left ventricular ejection fraction; MI = myocardial infarction;
PCI = percutaneous coronary intervention; CABG = coronary artery bypass graft surgery; NYHA = New
York Heart Association; TIA = transient ischemic attack; KCCQ-OS = Kansas City Cardiomyopathy
Questionnaire, Overall Summary Score; 5MWT = 5-meter walk time
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Table 2. Definitions of Complications Included in the Global Rank Composite Measure
Endpoint Component
Mortality

Definition
All-cause mortality

Stroke

Stroke defined by Valve Academic Research Consortium 2 (VARC-2)
criteria as an acute episode of a focal or global neurological deficit with
duration of ≥24 hours caused by ischemic, hemorrhagic, or undetermined
etiology and confirmed by neurological or neurosurgical specialist or
neuroimaging. Strokes were directly adjudicated by DCRI physicians.
Transient ischemic attack (TIA) was excluded.
Major Bleeding or Life-threatening or disabling bleeding was defined as
Bleeding Academic Research Consortium(BARC) 3a,b,or c or BARC 5
Acute Kidney Injury(AKI) was defined according to a modification of
Class III AKIN classification: Increase in serum creatinine to ≥300% (>3 ×
increase compared with baseline) OR serum creatinine of ≥4.0 mg/dL
(≥354 mmol/L) with an acute increase of at least 0.5 mg/dL (44 mmol/L)
Moderate aortic insufficiency or regurgitation is defined as the following:
Qualitative Measurements: Angiographic grade of 2+; Color Doppler jet
width greater than mild but no signs of severe aortic regurgitation
(insufficiency); Dopplar vena contracta width 0.3-0.6 cm; Quantitative
Measures (cath or echo) Regurgitant volume 30-59 ml/beat; Regurgitant
fraction 30-49%; Regurgitant orifice area 0.10-0.29 cm(2)

Bleeding Complication
Acute Kidney Injury

Moderate or Severe
Peri-valvular Leak
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Severe aortic insufficiency or regurgitation is defined as the following:
Qualitative Measurements: Angiographic grade of 3-4+; Color Doppler jet
width (Central jet) >65% of LVOT; Doppler vena contracta width >0.6 cm;.
Quantitative Measures (cath or echo) Regurgitant volume >=60 ml/beat;
Regurgitant fraction >=50%; Regurgitant orifice area >=0.30 cm(2)
Additional essential criteria: Left ventricular size is increased
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Table 3. Frequency of Global Ranking Categories in Study Cohort
Endpoint Ranking
1 = Death
2 = Stroke
3 = Bleeding Complication
4 = Acute Kidney Injury
5 = Moderate or Severe Peri-valvular leak
6 = None of the above
(Total N = 52,561)

Number
1671
1077
3024
336
1304
45149
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Percent
3.2%
2.0%
5.8%
0.6%
2.5%
85.9%
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Table 4. Adjusted Rates of 30-day complications according to overall site performance

Variables
Death
Stroke
Major or Life Threatening /Disabling Bleed
Acute Kidney Injury or New Dialysis

O/E Ratio (Observed* / Expected*)
Worse than
Better than Expected
As Expected
Expected
(Sites = 25)
(Sites = 242)
(Sites = 34)
(N = 7993)
(N = 37473)
(N = 7095)
0.71
1.01
1.25
(2.25% / 3.16%)
(3.21% / 3.17%) (4.06% / 3.26%)
0.73
1.03
1.29
(1.74% / 2.38%)
(2.49% / 2.41%) (3.16% / 2.44%)
0.45
1.02
2.13
(2.84% / 6.30%)
(6.48% / 6.33%) (13.6% / 6.38%)
0.67
1.12
1.17
(0.83% / 1.23%)
(1.34% / 1.20%) (1.44% / 1.23%)
0.77
1.19
2.00
(1.88% / 2.45%)
(2.71% / 2.28%) (4.76% / 2.38%)

Moderate or Severe Peri-valvular
Regurgitation
O/E ratio = observed to expected ratio
*Proportions represent observed rates and expected rates (based on risk-adjusted models for each
individual complication
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Figure Legends

Figure 1. Caterpillar Plot of Site-Specific Outcomes
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